A Phase 1, Multicenter, Open-label, 2-stage, Single-arm Study to Evaluate the Safety and Tolerability of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen and Preliminary Antitumor Activity of TIL in Pediatric, Adolescent, and Young Adult Participants With Relapsed or Refractory Solid Tumors
Latest Information Update: 27 Apr 2025
At a glance
- Drugs Lifileucel (Primary) ; LN 145 (Primary)
- Indications CNS cancer; Ewing's sarcoma; Malignant melanoma; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Iovance Biotherapeutics
Most Recent Events
- 27 Aug 2024 New trial record